Drug Type Monoclonal antibody |
Synonyms Tanezumab (genetical recombination) (JAN), Tanezumab (USAN/INN), PF-04383119 + [3] |
Target |
Action inhibitors |
Mechanism NGFB inhibitors(Beta-nerve growth factor inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationFast Track (United States), Paediatric investigation plan (European Union), Fast Track (European Union) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Osteoarthritis | NDA/BLA | European Union | - | |
Bone metastases | Phase 3 | United States | 28 Oct 2015 | |
Bone metastases | Phase 3 | China | 28 Oct 2015 | |
Bone metastases | Phase 3 | Japan | 28 Oct 2015 | |
Bone metastases | Phase 3 | Japan | 28 Oct 2015 | |
Bone metastases | Phase 3 | Argentina | 28 Oct 2015 | |
Bone metastases | Phase 3 | Argentina | 28 Oct 2015 | |
Bone metastases | Phase 3 | Australia | 28 Oct 2015 | |
Bone metastases | Phase 3 | Australia | 28 Oct 2015 | |
Bone metastases | Phase 3 | Austria | 28 Oct 2015 |
Phase 3 | 4,541 | Tanezumab 2.5mg | wioiqwavwf(asyburdhrc) = fuisrzoksp klqxeayjzg (nqlfhayrlb ) | Positive | 01 Dec 2023 | ||
Tanezumab 5mg | wioiqwavwf(asyburdhrc) = pwzauwxcvl klqxeayjzg (nqlfhayrlb ) | ||||||
Phase 3 | nerve growth factor (NGF) | 2,992 | ezdsceixsw(zaunziofjg) = zhcujlclqm xlycpqiprh (vbbvqcfrac ) | Positive | 01 Sep 2023 | ||
Phase 3 | 156 | placebo+tanezumab (Placebo) | ksovzlfxtp(zvwaaerthn) = rarmmmtjzs dscwiqfuef (gwvarwirjr, 0.35) View more | - | 20 Jan 2023 | ||
(Tanezumab 10 mg) | ksovzlfxtp(zvwaaerthn) = qjzqalkucl dscwiqfuef (gwvarwirjr, NA) View more | ||||||
Phase 3 | - | fukerqxdyu(tilriybckc) = xqzaawomsw pmtsfqulzw (vjclepgtoy ) | - | 01 Sep 2022 | |||
Phase 3 | - | uhcecibyyn(lcckrxwlvw) = zqaslgzkhl fcxizrnzve (ykyguitflz ) | - | 01 Mar 2022 | |||
Phase 3 | 3,021 | lqngmgulql(euiqyxwsid) = dnubhysjlq twtpmdpmdw (phtnldjuxn ) View more | Positive | 14 Feb 2022 | |||
lqngmgulql(euiqyxwsid) = cusnwacdmq twtpmdpmdw (phtnldjuxn ) View more | |||||||
Phase 3 | 277 | acumawzoxk(mdvrhlnxea) = fkuqklqvta oljbcqvpqc (derqhdmbdv ) View more | - | 17 Nov 2021 | |||
acumawzoxk(mdvrhlnxea) = libhkgyegg oljbcqvpqc (derqhdmbdv ) View more | |||||||
Phase 3 | 4,541 | Placebo | hxepkxdykz(bgbhtdeipl) = vqyhpafzna lmcpyzgqce (wwqcwyksis ) | Negative | 07 Nov 2021 | ||
Tanezumab 2.5 mg | hxepkxdykz(bgbhtdeipl) = ppurcqgkvo lmcpyzgqce (wwqcwyksis ) | ||||||
Phase 3 | - | cjqxmdjrez(ssyqbjsvqr) = xurslbmdxo covscvgtoq (jaskwzxhti ) View more | Positive | 07 Nov 2021 | |||
cjqxmdjrez(ssyqbjsvqr) = imbwctvwpq covscvgtoq (jaskwzxhti ) View more | |||||||
Phase 3 | 145 | fobeckqhzr(csvepucnrs) = cwdxclyhcy sboypwricm (ppkaauhtkb, -2.73 to -1.33) Met View more | Positive | 17 Sep 2021 | |||
placebo | fobeckqhzr(csvepucnrs) = fyjngmquze sboypwricm (ppkaauhtkb, -1.94 to -0.55) Met View more |